Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $192,103 | $165,453 | $149,824 | $174,159 |
| % Growth | 16.1% | 10.4% | -14% | – |
| Cost of Goods Sold | $48,331 | $16,827 | $15,763 | $26,098 |
| Gross Profit | $143,772 | $148,626 | $134,061 | $148,061 |
| % Margin | 74.8% | 89.8% | 89.5% | 85% |
| R&D Expenses | $29,366 | $22,115 | $26,927 | $28,647 |
| G&A Expenses | $0 | $28,421 | $26,666 | $24,816 |
| SG&A Expenses | $179,678 | $93,551 | $89,944 | $79,409 |
| Sales & Mktg Exp. | $0 | $65,130 | $63,278 | $54,593 |
| Other Operating Expenses | -$5,041 | $20,819 | $27,446 | $18,600 |
| Operating Expenses | $204,003 | $136,485 | $144,317 | $126,656 |
| Operating Income | -$60,231 | $12,141 | -$10,256 | $21,405 |
| % Margin | -31.4% | 7.3% | -6.8% | 12.3% |
| Other Income/Exp. Net | $2,277 | $4,528 | $4,425 | $4,977 |
| Pre-Tax Income | -$57,954 | $16,669 | -$5,831 | $26,382 |
| Tax Expense | -$12,837 | -$5,830 | $5,996 | $11,054 |
| Net Income | -$45,117 | $22,499 | -$11,827 | $15,328 |
| % Margin | -23.5% | 13.6% | -7.9% | 8.8% |
| EPS | -0.8 | 0.4 | -0.21 | 0.28 |
| % Growth | -300% | 290.5% | -175% | – |
| EPS Diluted | -0.8 | 0.4 | -0.21 | 0.27 |
| Weighted Avg Shares Out | 56,396 | 56,025 | 55,865 | 55,465 |
| Weighted Avg Shares Out Dil | 56,553 | 56,643 | 55,865 | 56,465 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,277 | $4,528 | $4,425 | $4,977 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $21,358 | $21,358 | $20,383 | $18,845 |
| EBITDA | -$36,596 | $33,499 | $17,787 | $45,227 |
| % Margin | -19.1% | 20.2% | 11.9% | 26% |